Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Fruquintinib, and Metronidazole in MSS/MSI-L Advanced Colorectal Cancer
NCT06356597Phase 2Active, not recruiting
- Sponsor
- Jing-yuan Fang
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, fruquintinib, metronidazole in colorectal cancer (CRC), sponsored by Jing-yuan Fang. Started Apr 2024; status: active, not recruiting.
02
Drugs
tislelizumabfruquintinibmetronidazole
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06356597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356597.